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Abstract  
The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. 
However, despite the undoubted potential held by these therapies, the balance between risk and 
benefit remains difficult to predict. As in any new field, a lack of previous application in man and 
gaps in the underlying science mean that regulators and investigators continue to look for a balance 
between minimizing potential risk and ensuring therapies are not needlessly kept from patients. 
Here, we attempt to identify the important safety issues, assessing the current advances in scientific 
knowledge and how these may translate to clinical therapeutic strategies in the identification and 
management of these risks. We also investigate the tools and techniques currently available to 
researchers during pre-clinical and clinical development of stem cell products, their utility and 
limitations and how these tools may be strategically used in the development of these therapies. 
We conclude that ensuring safety through cutting-edge science and robust assays, coupled with 
regular and open discussions between regulators and academic/industrial investigators are likely to 
prove the most fruitful route to ensuring the safest possible development of new products.  
Abbreviations: (human/murine) induced pluripotent stem cell, (h/m)iPSC; (human/murine) 
embryonic stem cell, (h/m)ESC; mesenchymal stem cell, MSC; hematopoietic stem cells, HSCs; adult 
stem cell, ASC; graft versus host disease, GVHD; major histocompatibility complex; MHC; minor 
histocompatibility complex, mHC; Oct4, Sox2, Klf4, c-Myc, OSKM; human leukocyte antigen, HLA; 
Magnetic Resonance imaging, MRI; computed tomography, CT; positron emission tomography, PET; 
single photon emission computed tomography, SPECT; superparamagnetic iron oxide particles, SPIO; 
9-[4-[18F]Fluoro-3-(hydroxymethyl)butyl]guanine, [18F]FHBG; perfuorcarbon, PFC; fluorine-19, 19 F;  
single nucleotide polymorphism, SNP; Food and drug administration, FDA; Medicines and healthcare 
products regulatory agency, MHRA. QD, quantum dots; G/RFP, green or red fluorescent protein 
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I. Introduction 
The field of stem cell therapeutics is moving towards widespread clinical application. Whilst it is vital 
that this development continues, the safety of these therapies must also be considered. Here we 
outline the known risks of stem-cell therapeutics (Figure S1) and discuss how they can be assessed 
and managed through preclinical and clinical trials. This review is the output of an IMI SafeSciMET 
workshop held at the University of Liverpool.  
II. Stem cell risk factors 
A key issue in the understanding of the safety concerns is the breadth of the human stem cell field, 
with several cell types falling under the umbrella term of ‘stem cell’: 
- Human embryonic stem cells ((h)ESCs) are pluripotent cells, first isolated from human 
embryos in 1998 by James Thompson1.  
- Induced pluripotent stem cells ((h)iPSCs) were first reported in 2006 by Shinya Yamanaka, 
demonstrating the reprogramming of somatic cells from mice and later humans, using 4 
transcription factors: Oct4, Sox2, Klf4 and c-Myc (OSKM), to a pluripotent stem cell-like 
state2, 3.  
- Adult stem cell (ASCs) covers several cell types including mesenchymal and 
hematopoietic stem cells and tissue-specific progenitors which reside in the human body 
throughout an individual’s life and in comparison to pluripotent stem cells, generally have 
a more limited expansion and differentiation capacity4, 5. 
Some adult stem cell-based therapies are clinically available, such as bone marrow transplants 
containing hematopoietic stem cells6, skin grafts for burns patients7, cord blood cells for blood disease 
therapies8 and mesenchymal stem cells for graft vs host disease (GVHD) in children (Canada and New 
Zealand)9.  
Additionally, over 3000 trials associated with stem cells are currently collated in the international 
clinical trial registry platform (www.who.int/trialsearch). The majority of these are adult stem cell-
based therapies, likely attributable to the longer established use of these cells. 
The registry also includes the first pluripotent-based therapies to be subjected to clinical trials; table 
1 highlights the narrow scope of these hESC-derived therapeutics, with 8 of the 9 treatments 
associated with macular dystrophy or degeneration. Moreover, the first human trial using hiPSCs has 
recently been approved for macular degeneration therapy10. This is due to the high retinal epithelial 
cell differentiation purity and the ease of access to the eye for treatment reducing the risk profile of 
the treatment, making it an ideal starting point for hESC/hiPSC therapies11, 12.  
Despite the basic technology being in place to produce a wider range of therapies, many aspects of 
the field, including safety, remain incompletely understood, contributing to the cautious translation 
from theoretical benefits to clinical application 
II.I Tumorigenic potential  
A major concern over the use of stem cell therapies is the perceived risk of tumorigenicity. This is 
exemplified by the investigation of a brain tumor which had developed in a child four years after being 
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treated with fetal neural stem cells for ataxia telangiectasia13. Subsequent analysis found that the 
tumor was derived from the transplanted material, thus demonstrating the risks which are associated 
with stem cell-based therapies.   
The capacity for undifferentiated pluripotent stem cells to form teratomas in vivo is of particular 
concern14. Therefore, it is unlikely that any therapy would directly transplant undifferentiated 
pluripotent stem cells, with in vitro differentiation the most likely route before transplantation. 
However, the risk remains that not all cells will be fully differentiated. One study showed that despite 
functional liver engraftment, hESC-derived hepatocyte-like cells transplanted into 
immunocompromised mice developed splenic and liver tumors containing endodermal and 
mesodermal cell types15. Teratomas have also been shown to be able to form from as little as 0.2% 
SSEA-1-positive pluripotent cells, demonstrating that, even at high levels of purity, teratoma 
formation potential remains16.  
It is therefore vital to prevent undifferentiated cells passing through to the differentiated cell 
population. Such techniques include small molecules targeting stearoyl-CoA desaturase-1, which 
selectively causes cell death in undifferentiated iPSC/ESCs17. However, the removal of all pluripotent 
cells cannot be confirmed with current analytical techniques as these are not reliably sensitive 
enough18. Therefore, it is important to take other factors, such as the disease and the number of cells 
transplanted into account, as this will likely alter the chances of subsequent teratoma formation. 
Recent work has alleviated some concerns, a non-human primate model for autologous transplants 
showed that iPSC-derived mesodermal stromal-like cells went on to form functional tissue, without 
teratoma formation19. 
Human studies are the only true way to ascertain the teratoma risk in man. The first human studies 
were conducted by Geron in 2009, using hESC-derived oligodendrocyte progenitor cells for spinal 
injury treatment20. Despite the trials having to be halted for financial reasons, no subsequent reports 
of tumor formation have emerged in those who were treated21. Clinical trials investigating the use of 
hESC- and iPSC-derived retinal pigmented epithelial cells in macular degeneration are currently 
ongoing11 and just starting10, respectively, with no tumorigenic safety concerns reported as yet. If 
successful, these trials are likely to alleviate some of the tumorigenic concerns surrounding 
pluripotent stem cells. 
Pluripotent cells can be cultured indefinitely in vitro, making scale-up production relatively 
straightforward. However, during expansion the cells are susceptible to chromosomal aberrations and 
karyotype abnormalities22-29, potentially due to the artificial conditions in which the cells are cultured, 
increasing the potential for post-transplant malignancy. Pioneering work has investigated these 
aberrations, commonly found at chromosomes 1, 12, 17 and 20, at higher resolution; however, it 
remains to be seen if the ‘culprit’ genes can be identified for screening23-25, 27-33. It is clear that smaller 
genomic changes also occur, often at a level not readily detected by standard G-banding23; the 
significance of these changes to safety is unclear. Much work has been focused on the removal of 
pluripotent stem cells from the transplanted material; however techniques which allow for the 
removal for genotypically compromised cells would be of equal benefit to the therapeutic safety 
profile34. Karyotypical changes are not limited to pluripotent cells, with ASCs also thought to develop 
abnormalities during in vitro culture31; however, these findings have been debated, as demonstrated 
by the correspondence between Sensebe et al.,35 and Ben-David et al.,36.  
5 
 
iPSCs have additional safety concerns. The development of non-integrative reprogramming 
techniques, utilizing direct transfection of proteins or mRNAs, Sendai viruses or episomal plasmids, 
has reduced concerns regarding incomplete promoter silencing and genomic disruptions of traditional 
techniques37-40. Some have also replaced the oncogenic-associated OSKM factors with Sall4, Nanog, 
Esrrb, and Lin2841; these factors are thought to be less efficient, but derive higher quality iPSCs with 
reduced aberrations in histone variant 2A.X, which has been shown to be a key determinant of 
iPSC/ESC quality and developmental potential42. Others have utilized microRNAs and small molecules 
to reprogram somatic cells43, 44; however, at the time of writing, these reports are yet to be repeated.  
Additional studies investigating the genomic integrity of iPSCs have shown that DNA damage sustained 
during reprogramming may not be fully repaired in the resulting cells45. Furthermore, reprogramming 
cord blood cells reduced the number of DNA mutations when compared to patient-derived dermal 
fibroblasts46, suggesting that reprogramming from neonatal material may be theoretically safer, albeit 
more challenging to obtain.  
II.II Immunogenic potential  
Maintaining immunological tolerance of stem cell transplants is crucial. Rejection is considered to be 
due to a mismatch in expression of human leukocyte antigens (HLA), minor histocompatibility complex 
(mHC) antigens and ABO blood group antigens following allogeneic transplant (Figure S2).  Generally, 
allogeneic matching for both HLA and mHC is not feasible due to extensive polymorphisms.  
Undifferentiated ASC immunogenicity studies are particularly important, as, unlike pluripotent cells, 
they can be administered without differentiation. MSCs have a unique capacity amongst ASCs to 
modulate the immune response through a HLA-independent47 dampening of inflammatory cytokine 
release48-50. Additional low HLA-I and no extracellular HLA-II48 alongside little or no expression of B- 
and T-cell co-stimulatory molecules51, 52 on MSCs, suggest a potential to both modulate and avoid 
immune surveillance. 
Hematopoietic stem cells (HSCs) have also demonstrated some immune avoidance capabilities53, 54. 
However, HSCs are known to be susceptible to GVHD and can be rejected, representing a major cause 
of patient morbidity and mortality55. Interestingly, MSCs have been used for the treatment of GVHD 
(Prochymal®)9, 56, 57. This has led some to suggest that MSCs could be used as part of the stem cell 
transplant to reduce the potential for graft rejection58 and has been shown to reduce T cell activation 
in animal models59. 
Due to tumorigenic risk, clinical administration of pluripotent stem cells is likely to be in the form of a 
differentiated population, thus any immunogenic assessment should focus on the resulting cell-type60. 
It is generally accepted that there is little to no immune rejection in autologous cells, even following 
in vitro culture. Therefore, research has focused on developing stem cells which are genetically 
identical to the recipient. Recently, somatic cell nuclear transfer was achieved in humans, allowing for 
the isolation of hESCs expressing the donor genotype61, 62. However, with mitochondrial DNA from the 
oocyte unaltered, complete mHC compatibility is unlikely, meaning that immunosuppressant therapy 
may be required.  
iPSC-based therapy remains the most promising technique to realizing pluripotent autologous 
therapy. Whilst initial reports suggested immunogenicity was still seen in syngeneic transplants63, two 
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subsequent studies found no evidence of acute or chronic immunogenicity towards differentiated 
iPSCs (both spontaneous and directed) when the cells were syngeneically administered to mice64, 65. 
Further, de Almeida et al., reported that, in contrast to rejected iPSCs, autologous iPSC-derived 
endothelial cells were accepted in mice, demonstrating a comparable tolerogenic response to primary 
endothelial cells66. Direct comparison of autologous and allogeneic transplanted iPSC-derived neurons 
in non-human primates also revealed minimal immune response in autologous transplants; whereas 
allogeneic transplants were immunogenic67. Therefore, current evidence points towards 
immunological tolerance of autologous terminally differentiated transplanted stem cells.  
The timescale and costs associated with personalized therapies may mean that they are used as an 
alternative option when HLA matching cannot be achieved from stem cell banks containing carefully 
selected donor cell-lines68-70. A second consideration is for disorders in which their etiology is 
genetically-linked, and whether patient-derived transplanted material containing the diseased 
genotype would have therapeutic efficacy; such cases may require gene correction technology, if HLA-
type cannot be matched, as shown to be possible in monogenic conditions such as alpha-1-antitrypsin 
deficiency71. 
One emerging method of overcoming these issues is through encapsulation of the transplanted cells72, 
73. This may reduce the risk of tumor formation and immune rejection, whilst maintaining efficacy 
through the movement of factors (e.g. cytokines) across a semi-permeable membrane. Such 
techniques are currently being developed for use in diseases such as diabetes and may represent an 
elegant solution to a complex problem74-77.  Notwithstanding the clear potential, the development of 
such a system is not trivial, and despite sustained efforts and sequential developments, the translation 
to a clinically effective technology has yet to be achieved78. 
II.III Biodistribution 
Biodistribution encompasses the migration, distribution, engraftment and long term survival of the 
transplanted material.     
Different routes of administration result in differential dissemination patterns; therefore, the 
appropriate method must be chosen, considering the target pathology and the therapeutic 
objectives79, 80. Systemic administration can lead to cells becoming entrapped in the lung or 
microvasculature, causing dangerous side-effects, such as the pulmonary embolisms reported 
following intravenous administration of adipose-tissue derived stem cells81. Therefore, the use of 
vasodilators82 or the administration in an artery close to the target tissue83, have been proposed to 
reduce these risks.  
However, arterial administration may still cause microvascular occlusions and thus, where possible, 
the ideal delivery method would be directly to the targeted organ/area84, 85. Such techniques allow for 
maximal cell delivery and therapeutic outcome; however, in organs such as the liver or pancreas, the 
invasive nature of the direct cell transplantation may require thorough risk-benefit assessments.  
Successful delivery may result in just 10% viability after transplantation due to physical stress, 
inflammation, hypoxia or immunogenic rejection18, meaning that very high numbers of cells may be 
required to achieve therapeutic benefit. As cell number increases, so does the potential for 
engraftment outside of the targeted tissues. It is therefore important to identify the cell location in 
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order to fully assess the consequences of ectopic engraftment. A recent study of neural stem cells in 
a rat model of spinal cord injury showed ectopic engraftment 9-10 weeks post-transplant at various 
points along the spinal cord and brainstem86. Due to their size these were hypothesised to have 
travelled in small numbers via the cerebral spinal fluid, colonized and further proliferated, highlighting 
the concerns regarding ectopic engraftment, even in a direct transplant model.  
 
The half-life of the transplanted material is another factor which can alter the level of risk. If short, the 
risk associated with the transplanted material is reduced accordingly. However, if the transplant does 
not have a capacity for long term survival and thus suffers from a loss of efficacy, chronic diseases may 
require repeated administration and thus an understanding of the likely dosing regime is another key 
consideration for risk assessment.  
 
III. Pre-clinical and clinical assessment  
One of the major limitations of stem cell therapeutics is the heterogeneous character and limited 
experience of their development. Consequently, there is currently no specific European (European 
Medicines Agency, EMA) or UK (Medicines and Healthcare Products Regulatory Agency, MHRA) 
regulatory guidance87 that addresses technical aspects of the drug development program in detail, 
e.g. type, size and duration of non-clinical studies. 
Regulators have attempted to address these problems by drafting guidelines and reflection papers, 
whenever the necessity becomes apparent. The “Guideline on human cell-based medicinal products 
(EMEA/CHMP/410869/2006)” was adopted in 2008, before the unifying regulation on advanced 
therapy a medicinal product came into force88, and gives a generic overview on the requirements for 
the licensing of cell-based medicinal products; however, the information provided is not very detailed. 
A subsequent reflection paper on stem cell-based medicinal products (CAT/571134/09) was adopted 
in 2011, focusing more specifically on stem-cell based medicinal products and also discusses the 
experiences gained with cell-based products, including a summary of the challenges associated with 
biodistribution and immunogenicity studies. However, since no detailed requirements are defined, 
the applicant is still required to implement an appropriate development program that addresses the 
product-specific risks.  
It is highly advisable that any institution aiming to initiate the development of a new product engages 
in early, open discussions with the regulatory bodies. Most regulatory agencies develop structures to 
facilitate the interaction with developers (e.g. the MHRA innovation office and the EMA innovation 
task force) and may provide scientific advice based on the concepts and already existing data to assist 
the product development process. 
For the development of advanced therapy medicinal products, a risk-based approach can be used as 
a matrix to decide which non-clinical data are needed based on the risk of the medicinal product. This 
is an optional pathway determined by the product developer, which encompasses the identification 
of the potential intrinsic (cell-related) and extrinsic (manufacture-related) risks associated with the 
medicinal product and the subsequent development and implementation of the appropriate assays 
to assess these risks.  
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This is further outlined in the “Guideline on the risk-based approach according to annex I, part IV of 
Directive 2001/83/EC applied to advanced therapy medicinal products” 
(EMA/CAT/CPWP/686637/2011). The annex of the guideline provides some non-exhaustive examples 
to better illustrate this concept. Likewise, (non-binding) guidance documents are also provided by the 
Food and Drug Administration (FDA) in the USA89. 
The importance of regulation is highlighted by the report on the unregulated use of fetal brain-derived 
olfactory ensheathing cells for the treatment for spinal cord injuries. The authors found little-to-no 
benefit from the treatment and complications, including meningitis and reports of patient mortality90. 
Whilst this is an extreme example, many unregulated stem cell treatments are now available across 
the world (well reviewed by Zarzeczny et al.,91). In 2011, Celltex® began offering ASC-based therapies 
in Texas, USA without FDA approval, igniting debate about the regulation of stem cell therapeutics92. 
Subsequently, the FDA has won a recent court battle to regulate proliferated stem cells as biological 
drugs and documents encapsulating these new regulatory powers are in preparation93, 94. 
III.I Tumorigenic and immunogenic pre-clinical and clinical trials/assays  
In terms of both tumor- and immunogenicity, risk is increased when the model is not predictive, so it 
is important to match the targeted disease phenotype to the animal or in vitro assay. Traditional 
medicinal product development routes may be appropriate (i.e. going from simple to complex, in vitro 
to in vivo and animal to human). However, some therapies may require multi-model studies to provide 
the fullest understanding of both efficacy and safety, whilst other therapies may not require an animal 
model as there may be little relevance. Future pre-clinical assessments may also use iPSC-derived cells 
as a source of a diseased phenotype as the most clinically relevant assay of therapeutic safety and 
efficacy.   
Tumorigenicity assays 
The tumorigenic potential of cell-based therapies needs to be assessed throughout product 
development. In vitro techniques, such as karyotyping, can be used to assess genomic integrity with 
regard to duplications, translocations and other chromosomal aberrations. More in-depth 
investigations may be required detect smaller changes; however, without known associated changes, 
attributing risk is difficult. Immune-deficient rodent models may be used to assess the tumorigenic 
potential of the transplanted material. Deep tissue assessment by q-PCR or histopathological analysis 
is usually required to confirm ectopic tumor formation95, 96, but future investigations may utilize 
improvements in real-time cell tracking for greater information with regard to tumor 
location/development, particularly in clinical trials. These techniques are evaluated in table 2. 
Additionally, a recent study showed that whilst teratomas were formed in immune-deficient models, 
immune-competent models rejected autologous iPSCs66; therefore formation of a human iPSC-derived 
teratoma in an immune-deficient pre-clinical model may not always translate to the clinical situation. 
The xenogeneic nature of such transplants may consequently require pre-clinical studies using 
syngeneic/allogeneic species-specific transplants19 before the development of human equivalents. 
Immunogenicity assays  
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Developing relevant immunogenicity assays remains challenging. Early in product development, using 
the equivalent therapy in a different species for autologous or allogeneic investigations, as shown by 
Morizane et al67, may provide the most informative results, if technically and financially viable.  
Immune-competent and immune-deficient in vivo models lack immunogenic clinical relevance for 
human cells in most situations; however, in some cases they can provide useful information: 
- Immune-competent models may be used to investigate the use of stem cells in immune-
privileged locations, such as the eye12 or as a model of allogeneic transplants.  
- Immune-deficient animals varying in the extent of immune-depletion(i.e. loss of specific 
immune cell types) may be useful in investigating specific mechanisms of rejection97.  
- Humanized models, such as the trimera mouse, have human immune cells, improving 
relevance98. However, such models would again be limited to allogeneic investigations. 
It is important to recognize that species differences and xenogeneic transplantation are likely to cause 
species-dependent translational issues in all discussed in vivo models99, potentially making in vitro 
assays, such as mixed lymphocyte reactions, more informative of the final human-based product.  
III.II Biodistribution in pre-clinical and clinical trial/assays 
Biodistribution informs both the efficacy and safety of the treatment. Whilst histopathology and PCR 
remain the gold standard for assessing deep tissues, here we focus on cell labelling due to its ability 
to monitor cell distribution/migration in real-time100. Such techniques are important for ascertaining 
the migratory/distribution patterns and are also informative in a tumorigenic (ectopic tumor 
formation) and immunogenic (loss of cells through immune rejection) context.   
Cellular imaging strategies are composed of the imaging technique and the labelling agent (figure S3). 
The imaging technique is usually chosen in conjunction with the labelling agent, which can be classified 
in two main categories: direct and indirect labelling101, summarized in table 3. 
Direct Labelling 
Direct labelling requires the introduction of the labelling agents into the cells before transplantation. 
The number of molecules introduced into the cell is then used as a surrogate for cell number. 
Radionuclides used for cell imaging have different physical half-lives, determining the length of time 
cells can be monitored non-invasively100; these are mainly detected using single photon emission 
computed tomography (SPECT) and/or positron emission tomography (PET; table 3). Studies have 
shown as little as 6.2x103-2.5x104 cells can be detected using these methods102. However, short 
radionuclide half-lives mean that cell-tracking is limited to hours rather than weeks. Indium-111 oxine 
has a relatively long half-life (~2.8 days)102 and has been shown to successfully track MSCs in preclinical 
models for up to 7 days103; however, signal leakage and alteration of cell phenotype limits 
translatability104. Clinically, hematopoietic stem cells labelled with 18F-FDG for acute and chronic 
myocardial infarction treatment were successfully tracked by PET after 20 hours105.  
The use of iron oxide-labelling for MRI is non-ionizing and makes it possible to trace the cells over 
longer periods of time106. The most common labelling agent in pre-clinical/clinical trials is 
superparamagnetic iron oxide particles (SPIO), which offers the highest sensitivity and has been used 
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to track neural stem cells in a patient for up to 3 weeks107. Generally, MRI has lower sensitivity than 
SPECT/PET. The number of cells used for SPIO tracking in man ranges from 3.71.x105 to 17.4x106 
cells108 whilst de Vries et al were able to detect 1.5x105 dendritic cells in vivo109. 
Alternatively, Perfuorcarbon (PFC) probes and contrast agent Fluorine-19 (19 F) can be used to label 
cells110. The low signal-to-noise ratio and the absence of background make the quantification of pool 
of cells feasible. The amount of 19 F typically varies between 1011 and 1013 per cell, potentially 
dependent on the cytoplasmic volume. Empirically, is has been estimated that the minimum sensitivity 
of cell detection would be 104-105  cells per voxel (value in a tri-dimensional grid)110. This system has 
been successfully exploited to monitor stem cells therapies111-113 and are promising for clinical 
applications110 with some PFC and Fluorine-19 approved by the FDA114. 
Indirect Labelling 
Indirect labelling is the introduction of a reporter gene encoding for a fluorescent protein or a product 
recognizable by a reporter probe18. This system is highly controllable because only viable cells are able 
to transcribe the reporter gene115.  
In MRI-based gene reporter systems, the transduced gene is typically an intracellular metalloprotein 
(e.g. transferrin, ferritin, tyrosinase), that traps large quantities of iron in the cytoplasm for non-
invasive detection100, 115. However, the trapped iron produces long-term background which masks the 
viability of the cell102.  Some have therefore suggested that the only transduced gene currently suitable 
for MRI cell tracking is Lysine-rich protein116.  
In the SPECT and PET reporter gene imaging systems, a gene reporter (enzyme or receptor) requires 
an exogenously administered probe (tracer) to allow the localization and quantification of the stem 
cell product. 
The most commonly used PET/SPECT reporter gene systems are: 
- Intracellular enzymes (e.g. herpes simplex virus 1 thymidine kinase) (PET/SPECT). 
- Mutant form of a dopamine receptor, a cell membrane protein that binds the radionuclide 
probe (3-(2’-[18F]-fluoroethyl)-spiperone)(PET). 
- Sodium-iodide symporter, a thyroid transmembrane protein, which transports iodine into the 
cell (PET and SPECT). 
A number of groups successfully monitored ESCs117 and MSCs118, 119 in animal models, using gene 
reporter systems. These studies reported a reliable correlation in terms of localization, magnitude and 
duration of the cells in vivo when compared to conventional methods (immunohistochemistry and 
PCR). The short half-life of the probes allows a defined continuous imaging period of no more than a 
few hours117. However, being non-invasive, monitoring of the stem cells at regular intervals was 
possible for up to 4 weeks117-119. Quantitative information can be extrapolated from the percentage of 
injected radioisotope/gram of tissue, allowing for the quantification of the area(s) covered by the cells, 
but not the exact cell number118. 
The use of indirect labelling is rare in a clinical setting as genomic alterations are required120. However, 
the FDA has approved the PET reporter probe 9-[4-[18F] Fluoro-3-(hydroxymethyl) butyl]guanine 
([18F]FHBG; IND #61,880)121 for the treatment of grade IV of glioblastoma multiforme. The group 
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successfully tracked the T-cells and also reported [18F]FHBG accumulation in the cytolytic T-cells121, 
with no significant adverse effects122. Guidelines on how to administer and safely monitor 18F-FHBG in 
humans have been made available123. 
Optical imaging techniques are limited by exponential signal loss as depth increases, caused by 
scattering phenomena that occur when photons pass through the tissue100, 115. Photoacoustic 
tomography overcomes this problem. A short laser pulse irradiates the target tissue, causing a partial 
absorption of the pulse energy and conversion into heat. This increases local pressure through 
thermo-elastic waves and is subsequently detected by ultrasonic transducers placed outside the 
tissue. The image is generated by collecting all thermo-elastic waves from the arrival time124, 125. Such 
technology has been used to track human MSCs labeled with gold nanocages in a rodent model 
successfully for 7 days126.  
III.III Other risks associated with the translation to the clinic  
Stem cells are not static products; consequently, cell culture and manufacturing conditions may 
introduce immunogenic alterations. For example, fetal bovine serum and sialic acid derivative Neu5G, 
found in stem cell culture conditions, have both been shown to alter the immunogenicity of stem 
cells127 128. Therefore, certified animal component-free products should be used wherever possible. 
Good Manufacturing Practice must also be followed, as well as microbiological control of clinical grade 
stem cell products and aspects of viral safety and other contaminants. Similar practices should be 
applied to pre-clinical research in order to allow predictable translation of therapies to the clinic. 
Despite highly-controlled conditions in both cell preparations and clinical settings, infections 
(commonly respiratory-related) remain a  risk for patients who have received allogeneic stem cell 
transplants which require immune-suppression therapy129. Further, the donor viral status must also 
be assessed, with screening for hepatitis and HIV commonplace in HSC transplants130.  
Scaffolds, aiding engraftment or delivery of cells, should also be considered for immunological 
potential. Such devices have been used to improve the survival of MSCs in brain injury models131, 132 
and some groups are attempting to use decellularized organs133 as 3D scaffolds for stem cell-derived 
repopulation134-136. Biological scaffolds offer greater similarity to the host extracellular matrix, 
improving engraftment; however, they are usually xenogeneic/allogeneic in origin137 and thus have 
immunogenic potential. Various techniques have been used in an attempt to remove/mask antigenic 
epitopes, DNA and damage-associated molecular pattern signals138-141. However, a comparative 
rodent study demonstrated that across 5 commercially available scaffolds, differential immunogenic 
responses were found, including chronic inflammation and fibrous tissue, all of which differed from 
an autologous control142. 
Scaffolds derived from synthetic origin are generally considered to be less immunogenic. Several 
synthetic biodegradable polymers have been approved by the FDA for medical applications143-145, and 
consequently may be used in the same site without further safety assessment. However, novel 
materials/uses are required to undergo safety testing in compliance with the ISO 10993 International 
Standard (ISO 10993: Biological evaluation of medical devices). 
IV. Conclusions 
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Stem cell therapies have the potential to offer alleviation from a range of chronic and debilitating 
diseases. Despite continued advances, much work remains in understanding and reducing the risks 
associated with stem cell therapeutics. 
Improvements in in vitro techniques are required, such as gene aberration-free expansion and 
improved differentiation purity alongside the identification of risk factors which can be routinely 
screened before transplantation. Further, models which can better predict immunological responses 
and cell imaging techniques with increased duration and depth capabilities would also be beneficial.  
However, this work must remain focused on the clinical outcome. The most important consideration 
is the risk-benefit assessment for the patient as whilst the cells, like many drugs, may not be perfectly 
safe, the patient benefit may far outweigh the potential risks. Therefore, each treatment should be 
determined on a case-by-case basis with regulatory input, ensuring that the risk of the therapy is 
appropriate for the given condition and patient. 
Acknowledgements 
The review article was supported by the SafeSciMet programme, a European Community project 
under the Innovative Medicines Initiative (IMI) Programme through Grant Agreement number 
115012. Additional support was provided by the Medical Research Council Centre for Drug Safety 
Science (grant number G0700654) and the UK Regenerative Medicine Platform Safety Hub (grant 
number MR/K026739/1). 
References 
 
1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human 
blastocysts. Science. 1998;282:1145-1147. 
2. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and 
Adult Fibroblast Cultures by Defined Factors. Cell. 2006;126:663-676. 
3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of Pluripotent Stem Cells from Adult Human 
Fibroblasts by Defined Factors. Cell. 2007;131:861-872. 
4. Sarugaser R, Hanoun L, Keating A, et al. Human Mesenchymal Stem Cells Self-Renew and 
Differentiate According to a Deterministic Hierarchy. PLoS ONE. 2009;4:e6498. 
5. Huber TL. Dissecting hematopoietic differentiation using the embryonic stem cell 
differentiation model. Int J Dev Biol. 2010;54:991-1002. 
6. Copelan EA. Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine. 
2006;354:1813-1826. 
7. Gallico GG, O'Connor NE, Compton CC, et al. Permanent Coverage of Large Burn Wounds with 
Autologous Cultured Human Epithelium. New England Journal of Medicine. 1984;311:448-
451. 
13 
 
8. Chao NJ, Emerson SG, Weinberg KI. Stem Cell Transplantation (Cord Blood Transplants). ASH 
Education Program Book. 2004;2004:354-371. 
9. Zheng G-P, Ge M-H, Shu Q, et al. Mesenchymal stem cells in the treatment of pediatric 
diseases. World J Pediatr. 2013;9:197-211. 
10. Cyranoski D. Next-generation stem cells cleared for human trial. Nature. 2014. 
11. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular 
degeneration: a preliminary report. Lancet. 2012;379:713-720. 
12. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of 
nature. Nature reviews. Immunology. 2003;3:879-889. 
13. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-Derived Brain Tumor Following Neural 
Stem Cell Transplantation in an Ataxia Telangiectasia Patient. PLoS Med. 2009;6:e1000029. 
14. Andrews PW, Matin MM, Bahrami AR, et al. Embryonic stem (ES) cells and embryonal 
carcinoma (EC) cells: opposite sides of the same coin. Biochemical Society transactions. 
2005;33:1526-1530. 
15. Payne CM, Samuel K, Pryde A, et al. Persistence of functional hepatocyte-like cells in immune-
compromised mice. Liver International. 2011;31:254-262. 
16. Fujikawa T, Oh S-H, Pi L, et al. Teratoma Formation Leads to Failure of Treatment for Type I 
Diabetes Using Embryonic Stem Cell-Derived Insulin-Producing Cells. The American Journal of 
Pathology. 2005;166:1781-1791. 
17. Ben-David U, Gan QF, Golan-Lev T, et al. Selective Elimination of Human Pluripotent Stem Cells 
by an Oleate Synthesis Inhibitor Discovered in a High-Throughput Screen. Cell Stem Cell. 
2013;12:167-179. 
18. Nguyen PK, Nag D, Wu JC. Methods to assess stem cell lineage, fate and function. Advanced 
drug delivery reviews. 2010;62:1175-1186. 
19. Hong So G, Winkler T, Wu C, et al. Path to the Clinic: Assessment of iPSC-Based Cell Therapies 
In Vivo in a Nonhuman Primate Model. Cell Reports. 2014. 
20. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotech. 
2009;27:213-214. 
21. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotech. 2012;30:12-
13. 
22. Sverdlov ED, Mineev K. Mutation rate in stem cells: an underestimated barrier on the way to 
therapy. Trends in Molecular Medicine. 2013;19:273-280. 
14 
 
23. Amps K, Andrews PW, Anyfantis G, et al. Screening ethnically diverse human embryonic stem 
cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nature 
Biotechnology. 2011;29:1132-1144. 
24. Ben-David U, Benvenisty N. High Prevalence of Evolutionarily Conserved and Species-Specific 
Genomic Aberrations in Mouse Pluripotent Stem Cells. Stem Cells. 2012;30:612-622. 
25. Fazeli A, Liew CG, Matin MM, et al. Altered patterns of differentiation in karyotypically 
abnormal human embryonic stem cells. International Journal of Developmental Biology. 
2011;55:175-180. 
26. Hovatta O, Jaconi M, Töhönen V, et al. A Teratocarcinoma-Like Human Embryonic Stem Cell 
(hESC) Line and Four hESC Lines Reveal Potentially Oncogenic Genomic Changes. PLoS ONE. 
2010;5:e10263. 
27. Lund RJ, Nikula T, Rahkonen N, et al. High-throughput karyotyping of human pluripotent stem 
cells. Stem Cell Research. 2012;9:192-195. 
28. Mayshar Y, Ben-David U, Lavon N, et al. Identification and Classification of Chromosomal 
Aberrations in Human Induced Pluripotent Stem Cells. Cell stem cell. 2010;7:521-531. 
29. Närvä E, Autio R, Rahkonen N, et al. High-resolution DNA analysis of human embryonic stem 
cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nature 
Biotechnology. 2010;28:371-377. 
30. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent 
stem cells. Nature Reviews Cancer. 2011;11:268-277. 
31. Ben-David U, Mayshar Y, Benvenisty N. Large-Scale Analysis Reveals Acquisition of Lineage-
Specific Chromosomal Aberrations in Human Adult Stem Cells. Cell stem cell. 2011;9:97-102. 
32. Hyka-Nouspikel N, Desmarais J, Gokhale PJ, et al. Deficient DNA Damage Response and Cell 
Cycle Checkpoints Lead to Accumulation of Point Mutations in Human Embryonic Stem Cells. 
Stem Cells. 2012;30:1901-1910. 
33. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured 
human embryonic stem cells. Nat Biotechnol. 2004;22:53-54. 
34. Lee AS, Tang C, Rao MS, et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell 
therapies. Nature medicine. 2013;19:998-1004. 
35. Sensebé L, Tarte K, Galipeau J, et al. Limited acquisition of chromosomal aberrations in human 
adult mesenchymal stromal cells. Cell Stem Cell. 2012;10:9-10. 
36. Ben-David U, Mayshar Y, Benvenisty N. Significant Acquisition of Chromosomal Aberrations in 
Human Adult Mesenchymal Stem Cells: Response to Sensebé et al. Cell Stem Cell. 2012;10:10-
11. 
15 
 
37. González F, Boué S, Belmonte JCI. Methods for making induced pluripotent stem cells: 
Reprogramming à la carte. Nature Reviews Genetics. 2011;12:231-242. 
38. Warren L, Manos PD, Ahfeldt T, et al. Highly Efficient Reprogramming to Pluripotency and 
Directed Differentiation of Human Cells with Synthetic Modified mRNA. Cell stem cell. 
2010;7:618-630. 
39. Kim D, Kim C-H, Moon J-I, et al. Generation of Human Induced Pluripotent Stem Cells by Direct 
Delivery of Reprogramming Proteins. Cell stem cell. 2009;4:472-476. 
40. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent 
stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the 
host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:348-362. 
41. Buganim Y, Markoulaki S, van Wietmarschen N, et al. The Developmental Potential of iPSCs Is 
Greatly Influenced by Reprogramming Factor Selection. Cell Stem Cell. 2014;15:295-309. 
42. Wu T, Liu Y, Wen D, et al. Histone Variant H2A.X Deposition Pattern Serves as a Functional 
Epigenetic Mark for Distinguishing the Developmental Potentials of iPSCs. Cell Stem Cell. 
2014;15:281-294. 
43. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency 
using mature microRNAs. Cell Stem Cell. 2011;8:633-638. 
44. Hou P, Li Y, Zhang X, et al. Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-
Molecule Compounds. Science. 2013;341:651-654. 
45. González F, Georgieva D, Vanoli F, et al. Homologous Recombination DNA Repair Genes Play 
a Critical Role in Reprogramming to a Pluripotent State. Cell Reports. 2013;3:651-660. 
46. Su R-J, Yang Y, Neises A, et al. Few Single Nucleotide Variations in Exomes of Human Cord 
Blood Induced Pluripotent Stem Cells. PLoS ONE. 2013;8:e59908. 
47. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed 
lymphocyte cultures and mitogenic responses independently of the major histocompatibility 
complex. Scandinavian journal of immunology. 2003;57:11-20. 
48. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of 
differentiated and undifferentiated mesenchymal stem cells. Experimental hematology. 
2003;31:890-896. 
49. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell 
responses. Blood. 2005;105:1815-1822. 
50. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte 
proliferation in vitro and prolong skin graft survival in vivo. Experimental hematology. 
2002;30:42-48. 
16 
 
51. Majumdar MK, Keane-Moore M, Buyaner D, et al. Characterization and functionality of cell 
surface molecules on human mesenchymal stem cells. Journal of biomedical science. 
2003;10:228-241. 
52. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by 
human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-
397. 
53. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic 
stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271-285. 
54. Zheng J, Umikawa M, Zhang S, et al. Ex vivo expanded hematopoietic stem cells overcome the 
MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9:119-130. 
55. Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after 
allogeneic hematopoietic stem cell transplantation. Expert opinion on pharmacotherapy. 
2014;15:23-36. 
56. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host 
disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441. 
57. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, 
severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586. 
58. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem 
cell transplantation. Experimental & molecular medicine. 2013;45:e2. 
59. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem cells support unrelated donor 
hematopoietic stem cells and suppress T-cell activation. Bone marrow transplantation. 
2004;33:597-604. 
60. Draper JS, Pigott C, Thomson JA, et al. Surface antigens of human embryonic stem cells: 
changes upon differentiation in culture. Journal of anatomy. 2002;200:249-258. 
61. Tachibana M, Amato P, Sparman M, et al. Human Embryonic Stem Cells Derived by Somatic 
Cell Nuclear Transfer. Cell. 2013;153:1228-1238. 
62. Chung Young G, Eum Jin H, Lee Jeoung E, et al. Human Somatic Cell Nuclear Transfer Using 
Adult Cells. Cell Stem Cell. 2014;14:777-780. 
63. Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature. 
2011;474:212-215. 
64. Guha P, Morgan JW, Mostoslavsky G, et al. Lack of immune response to differentiated cells 
derived from syngeneic induced pluripotent stem cells. Cell Stem Cell. 2013;12:407-412. 
65. Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells 
derived from induced pluripotent or embryonic stem cells. Nature. 2013;494:100-104. 
17 
 
66. de Almeida PE, Meyer EH, Kooreman NG, et al. Transplanted terminally differentiated induced 
pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat 
Commun. 2014;5. 
67. Morizane A, Doi D, Kikuchi T, et al. Direct Comparison of Autologous and Allogeneic 
Transplantation of iPSC-Derived Neural Cells in the Brain of a Nonhuman Primate. Stem Cell 
Reports. 2013;1:283-292. 
68. Taylor CJ, Bolton EM, Pocock S, et al. Banking on human embryonic stem cells: estimating the 
number of donor cell lines needed for HLA matching. Lancet. 2005;366:2019-2025. 
69. Taylor Craig J, Peacock S, Chaudhry Afzal N, et al. Generating an iPSC Bank for HLA-Matched 
Tissue Transplantation Based on Known Donor and Recipient HLA Types. Cell stem cell. 
2012;11:147-152. 
70. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nature 
Biotechnology. 2008;26:739-740. 
71. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha-1-antitrypsin 
deficiency in induced pluripotent stem cells. Nature. 2011;478:391-394. 
72. Zhang W, Zhao S, Rao W, et al. A novel core-shell microcapsule for encapsulation and 3D 
culture of embryonic stem cells. Journal of Materials Chemistry B. 2013;1:1002-1009. 
73. Salick M, Boyer R, Koonce C, et al. Differentiation of Human Embryonic Stem Cells 
Encapsulated in Hydrogel Matrix Materials. In: Proulx T, ed. Experimental and Applied 
Mechanics, Volume 6: Springer New York; 2011:415-421. 
74. Tuch BE, Hughes TC, Evans MDM. Encapsulated pancreatic progenitors derived from human 
embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes/Metabolism 
Research and Reviews. 2011;27:928-932. 
75. Schulz TC, Young HY, Agulnick AD, et al. A Scalable System for Production of Functional 
Pancreatic Progenitors from Human Embryonic Stem Cells. PLoS ONE. 2012;7:e37004. 
76. Lee SH, Hao E, Savinov AY, et al. Human beta-cell precursors mature into functional insulin-
producing cells in an immunoisolation device: implications for diabetes cell therapies. 
Transplantation. 2009;87:983-991. 
77. Kirk K, Hao E, Lahmy R, et al. Human embryonic stem cell derived islet progenitors mature 
inside an encapsulation device without evidence of increased biomass or cell escape. Stem 
Cell Research. 2014;12:807-814. 
78. Freimark D, Pino-Grace P, Pohl S, et al. Use of Encapsulated Stem Cells to Overcome the 
Bottleneck of Cell Availability for Cell Therapy Approaches. Transfusion medicine and 
18 
 
hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und 
Immunhamatologie. 2010;37:66-73. 
79. Moscoso I, Barallobre J, de Ilarduya OM, et al. Analysis of different routes of administration of 
heterologous 5-azacytidine-treated mesenchymal stem cells in a porcine model of myocardial 
infarction. Transplantation proceedings. 2009;41:2273-2275. 
80. Li L, Jiang Q, Ding GL, et al. Effects of administration route on migration and distribution of 
neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. J 
Cerebr Blood F Met. 2010;30:653-662. 
81. Jung JW, Kwon M, Choi JC, et al. Familial Occurrence of Pulmonary Embolism after 
Intravenous, Adipose Tissue-Derived Stem Cell Therapy. Yonsei Med J. 2013;54:1293-1296. 
82. Schrepfer S, Deuse T, Reichenspurner H, et al. Stem Cell Transplantation: The Lung Barrier. 
Transplantation proceedings. 2007;39:573-576. 
83. Syková E, Jendelová P, Urdzíková L, et al. Bone marrow stem cells and polymer hydrogels - 
Two strategies for spinal cord injury repair. Cellular and Molecular Neurobiology. 
2006;26:1113-1129. 
84. Walczak P, Zhang J, Gilad AA, et al. Dual-modality monitoring of targeted intraarterial delivery 
of mesenchymal stem cells after transient ischemia. Stroke. 2008;39:1569-1574. 
85. Bacou F, Boubaker El Andalousi R, Daussin PA, et al. Transplantation of Adipose Tissue-Derived 
Stromal Cells Increases Mass and Functional Capacity of Damaged Skeletal Muscle. Cell 
Transplant. 2004;13:103-111. 
86. Steward O, Sharp Kelli G, Matsudaira Yee K. Long-Distance Migration and Colonization of 
Transplanted Neural Stem Cells. Cell. 2014;156:385-387. 
87. Goldring CE, Duffy PA, Benvenisty N, et al. Assessing the safety of stem cell therapeutics. Cell 
Stem Cell. 2011;8:618-628. 
88. Hyun I, Lindvall O, Ährlund-Richter L, et al. New ISSCR Guidelines Underscore Major Principles 
for Responsible Translational Stem Cell Research. Cell stem cell. 2008;3:607-609. 
89. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. The New England journal 
of medicine. 2006;355:1730-1735. 
90. Dobkin BH, Curt A, Guest J. Cellular Transplants in China: Observational Study from the Largest 
Human Experiment in Chronic Spinal Cord Injury. Neurorehabilitation and Neural Repair. 
2006;20:5-13. 
91. Zarzeczny A, Caulfield T, Ogbogu U, et al. Professional Regulation: A Potentially Valuable Tool 
in Responding to “Stem Cell Tourism”. Stem Cell Reports.3:379-384. 
92. Cyranoski D. Stem cells in Texas: Cowboy culture. Nature. 2013;494:166-168. 
19 
 
93. Cyranoski D. FDA's claims over stem cells upheld. Nature. 2012;487:14. 
94. Nature News. Biomedical briefing. Nature medicine. 2014;20:226-227. 
95. MacIsaac ZM, Shang H, Agrawal H, et al. Long-term in-vivo tumorigenic assessment of human 
culture-expanded adipose stromal/stem cells. Experimental cell research. 2012;318:416-423. 
96. Kanemura H, Go MJ, Shikamura M, et al. Tumorigenicity Studies of Induced Pluripotent Stem 
Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related 
Macular Degeneration. PLoS ONE. 2014;9:e85336. 
97. Sharpe ME, Morton D, Rossi A. Nonclinical safety strategies for stem cell therapies. Toxicol 
Appl Pharmacol. 2012;262:223-231. 
98. Reisner Y, Dagan S. The Trimera mouse: generating human monoclonal antibodies and an 
animal model for human diseases. Trends in biotechnology. 1998;16:242-246. 
99. Macchiarini F, Manz MG, Palucka AK, et al. Humanized mice: are we there yet? The Journal of 
experimental medicine. 2005;202:1307-1311. 
100. Rodriguez-Porcel M, Wu JC, Gambhir SS. Molecular imaging of stem cells. StemBook. 
Cambridge (MA); 2008. 
101. Kuchmiy AA, Efimov GA, Nedospasov SA. Methods for in vivo molecular imaging. Biochemistry. 
Biokhimiia. 2012;77:1339-1353. 
102. Kraitchman DL, Bulte JW. In vivo imaging of stem cells and Beta cells using direct cell labeling 
and reporter gene methods. Arteriosclerosis, thrombosis, and vascular biology. 2009;29:1025-
1030. 
103. Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic Imaging of Allogeneic Mesenchymal 
Stem Cells Trafficking to Myocardial Infarction. Circulation. 2005;112:1451-1461. 
104. Brenner W, Aicher A, Eckey T, et al. 111In-Labeled CD34+ Hematopoietic Progenitor Cells in a 
Rat Myocardial Infarction Model. Journal of Nuclear Medicine. 2004;45:512-518. 
105. Kang WJ, Kang HJ, Kim HS, et al. Tissue distribution of 18F-FDG-labeled peripheral 
hematopoietic stem cells after intracoronary administration in patients with myocardial 
infarction. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 
2006;47:1295-1301. 
106. McColgan P, Sharma P, Bentley P. Stem Cell Tracking in Human Trials: A Meta-Regression. 
Stem Cell Rev Rep. 2011;7:1031-1040. 
107. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. The New 
England journal of medicine. 2006;355:2376-2378. 
108. Zhang WY, Ebert AD, Narula J, et al. Imaging cardiac stem cell therapy: translations to human 
clinical studies. Journal of cardiovascular translational research. 2011;4:514-522. 
20 
 
109. de Vries IJM, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells 
in melanoma patients for monitoring of cellular therapy. Nat Biotech. 2005;23:1407-1413. 
110. Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 
detection. NMR in biomedicine. 2013;26:860-871. 
111. Partlow KC, Chen J, Brant JA, et al. 19F magnetic resonance imaging for stem/progenitor cell 
tracking with multiple unique perfluorocarbon nanobeacons. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology. 2007;21:1647-
1654. 
112. Boehm-Sturm P, Mengler L, Wecker S, et al. In vivo tracking of human neural stem cells with 
19F magnetic resonance imaging. PLoS One. 2011;6:e29040. 
113. Bible E, Dell'Acqua F, Solanky B, et al. Non-invasive imaging of transplanted human neural 
stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and 
diffusion-MRI. Biomaterials. 2012;33:2858-2871. 
114. Ruiz-Cabello J, Barnett BP, Bottomley PA, et al. Fluorine (19F) MRS and MRI in biomedicine. 
NMR in biomedicine. 2011;24:114-129. 
115. Gu E, Chen WY, Gu J, et al. Molecular imaging of stem cells: tracking survival, biodistribution, 
tumorigenicity, and immunogenicity. Theranostics. 2012;2:335-345. 
116. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based 
on proton exchange. Nat Biotech. 2007;25:217-219. 
117. Wu JC, Spin JM, Cao F, et al. Transcriptional profiling of reporter genes used for molecular 
imaging of embryonic stem cell transplantation. Physiological genomics. 2006;25:29-38. 
118. Gyongyosi M, Blanco J, Marian T, et al. Serial noninvasive in vivo positron emission 
tomographic tracking of percutaneously intramyocardially injected autologous porcine 
mesenchymal stem cells modified for transgene reporter gene expression. Circulation. 
Cardiovascular imaging. 2008;1:94-103. 
119. Pei Z, Lan X, Cheng Z, et al. Multimodality Molecular Imaging to Monitor Transplanted Stem 
Cells for the Treatment of Ischemic Heart Disease. PLoS ONE. 2014;9:e90543. 
120. Ray P, De A. Reporter Gene Imaging in Therapy and Diagnosis. Theranostics. 2012;2:333-334. 
121. Yaghoubi SS, Campbell DO, Radu CG, et al. Positron Emission Tomography Reporter Genes and 
Reporter Probes: Gene and Cell Therapy Applications. Theranostics. 2012;2:374-391. 
122. Yaghoubi SS, Couto MA, Chen CC, et al. Preclinical safety evaluation of 18F-FHBG: a PET 
reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant 
HSV1-sr39tk's expression. Journal of nuclear medicine : official publication, Society of Nuclear 
Medicine. 2006;47:706-715. 
21 
 
123. Yaghoubi SS, Gambhir SS. PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-
tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG. 
Nat Protoc. 2006;1:3069-3075. 
124. Wang L, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 
(New York, N.Y.). 2012;335:1458-1462. 
125. Yao J, Wang LV. Photoacoustic tomography: fundamentals, advances and prospects. Contrast 
media & molecular imaging. 2011;6:332-345. 
126. Zhang YS, Wang Y, Wang L, et al. Labeling human mesenchymal stem cells with gold nanocages 
for in vitro and in vivo tracking by two-photon microscopy and photoacoustic microscopy. 
Theranostics. 2013;3:532-543. 
127. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal 
cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for 
cell therapy of bone. Proceedings of the National Academy of Sciences of the United States of 
America. 2002;99:8932-8937. 
128. Martin MJ, Muotri A, Gage F, et al. Human embryonic stem cells express an immunogenic 
nonhuman sialic acid. Nature medicine. 2005;11:228-232. 
129. Dokos C, Masjosthusmann K, Rellensmann G, et al. Fatal human metapneumovirus infection 
following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease. 
2013;15:E97-E101. 
130. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections 
among hematopoietic stem cell transplant recipients. MMWR. Recommendations And 
Reports: Morbidity And Mortality Weekly Report. Recommendations And Reports / Centers 
For Disease Control. Vol 49. United States: U.S. Dept. of Health and Human Services, Public 
Health Service, Centers for Disease Control, Epidemiology Program Office; 2000:1. 
131. Tate CC, Shear DA, Tate MC, et al. Laminin and fibronectin scaffolds enhance neural stem cell 
transplantation into the injured brain. Journal of tissue engineering and regenerative 
medicine. 2009;3:208-217. 
132. Guan J, Zhu Z, Zhao RC, et al. Transplantation of human mesenchymal stem cells loaded on 
collagen scaffolds for the treatment of traumatic brain injury in rats. Biomaterials. 
2013;34:5937-5946. 
133. Guyette JP, Gilpin SE, Charest JM, et al. Perfusion decellularization of whole organs. Nat 
Protoc. 2014;9:1451-1468. 
22 
 
134. Zhou Q, Li L, Li J. Stem cells with decellularized liver scaffolds in liver regeneration and their 
potential clinical applications. Liver international : official journal of the International 
Association for the Study of the Liver. 2014. 
135. Sabetkish S, Kajbafzadeh AM, Sabetkish N, et al. Whole-organ tissue engineering: 
Decellularization and recellularization of three-dimensional matrix liver scaffolds. Journal of 
biomedical materials research. Part A. 2014. 
136. Bonandrini B, Figliuzzi M, Papadimou E, et al. Recellularization of well-preserved acellular 
kidney scaffold using embryonic stem cells. Tissue engineering. Part A. 2014;20:1486-1498. 
137. Badylak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: 
Structure and function. Acta biomaterialia. 2009;5:1-13. 
138. Fishman JM, Lowdell MW, Urbani L, et al. Immunomodulatory effect of a decellularized 
skeletal muscle scaffold in a discordant xenotransplantation model. Proceedings of the 
National Academy of Sciences of the United States of America. 2013;110:14360-14365. 
139. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization 
processes. Biomaterials. 2011;32:3233-3243. 
140. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med. 
2011;17:424-432. 
141. Daly KA, Liu S, Agrawal V, et al. Damage associated molecular patterns within xenogeneic 
biologic scaffolds and their effects on host remodeling. Biomaterials. 2012;33:91-101. 
142. Valentin JE, Badylak JS, McCabe GP, et al. Extracellular matrix bioscaffolds for orthopaedic 
applications. A comparative histologic study. The Journal of bone and joint surgery. American 
volume. 2006;88:2673-2686. 
143. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell 
Mater. 2003;5:1-16. 
144. Willerth SM, Sakiyama-Elbert SE. Combining stem cells and biomaterial scaffolds for 
constructing tissues and cell delivery. StemBook. Cambridge (MA); 2008. 
145. Demirbag B, Huri PY, Kose GT, et al. Advanced cell therapies with and without scaffolds. 
Biotechnology journal. 2011;6:1437-1453. 
146. Ben-David U, Mayshar Y, Benvenisty N. Virtual karyotyping of pluripotent stem cells on the 
basis of their global gene expression profiles. Nature Protocols. 2013;8:989-997. 
147. Hay DC, Pernagallo S, Diaz-Mochon JJ, et al. Unbiased screening of polymer libraries to define 
novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res. 
2011;6:92-102. 
23 
 
148. Desmarais JA, Hoffmann MJ, Bingham G, et al. Human Embryonic Stem Cells Fail to Activate 
CHK1 and Commit to Apoptosis in Response to DNA Replication Stress. Stem Cells. 
2012;30:1385-1393. 
149. Tang C, Lee AS, Volkmer JP, et al. An antibody against SSEA-5 glycan on human pluripotent 
stem cells enables removal of teratoma-forming cells. Nature Biotechnology. 2011;29:829-
834. 
150. Ben-David U, Nudel N, Benvenisty N. Immunologic and chemical targeting of the tight-junction 
protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nature 
Communications. 2013;4. 
151. Benevento M, Munoz J. Role of mass spectrometry-based proteomics in the study of cellular 
reprogramming and induced pluripotent stem cells. Expert Rev Proteomics. 2012;9:379-399. 
152. Reiland S, Salekdeh GH, Krijgsveld J. Defining pluripotent stem cells through quantitative 
proteomic analysis. Expert Rev Proteomics. 2011;8:29-42. 
153. Sinden JD, Muir KW. Stem cells in stroke treatment: the promise and the challenges. Int J 
Stroke. 2012;7:426-434. 
154. Wang LV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science. 
2012;335:1458-1462. 
155. de Almeida PE, van Rappard JR, Wu JC. In vivo bioluminescence for tracking cell fate and 
function. American journal of physiology. Heart and circulatory physiology. 2011;301:H663-
671. 
156. Welling MM, Duijvestein M, Signore A, et al. In vivo biodistribution of stem cells using 
molecular nuclear medicine imaging. J Cell Physiol. 2011;226:1444-1452. 
157. Cromer Berman SM, Walczak P, Bulte JW. Tracking stem cells using magnetic nanoparticles. 
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. 2011;3:343-355. 
158. Rosen AB, Kelly DJ, Schuldt AJT, et al. Finding Fluorescent Needles in the Cardiac Haystack: 
Tracking Human Mesenchymal Stem Cells Labeled with Quantum Dots for Quantitative In Vivo 
Three-Dimensional Fluorescence Analysis. Stem Cells. 2007;25:2128-2138. 
159. Lin S, Xie X, Patel MR, et al. Quantum dot imaging for embryonic stem cells. BMC Biotechnol. 
2007;7:67. 
160. Eisenblätter M, Ehrchen J, Varga G, et al. In Vivo Optical Imaging of Cellular Inflammatory 
Response in Granuloma Formation Using Fluorescence-Labeled Macrophages. Journal of 
Nuclear Medicine. 2009;50:1676-1682. 
161. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and 
applications. Physiol Rev. 2012;92:897-965. 
24 
 
162. Zinn KR, Chaudhuri TR, Szafran AA, et al. Noninvasive Bioluminescence Imaging in Small 
Animals. ILAR Journal. 2008;49:103-115. 
163. Eghtedari M, Oraevsky A, Copland JA, et al. High Sensitivity of In Vivo Detection of Gold 
Nanorods Using a Laser Optoacoustic Imaging System. Nano letters. 2007;7:1914-1918. 
164. Chamberland DL, Agarwal A, Kotov N, et al. Photoacoustic tomography of joints aided by an 
Etanercept-conjugated gold nanoparticle contrast agent-an ex vivo preliminary rat study. 
Nanotechnology. 2008;19:095101. 
 
Figure legends 
Figure S1: Therapeutic risks of stem cells. Diagram demonstrating the main inherent safety concerns 
associated with stem cell therapeutics. These can be divided into 3 main categories: biodistribution: 
cell migration, distribution, engraftment and long-term survival; immunogenicity: graft-vs-host 
disease and other inflammatory/fibrotic conditions; tumorigenicity: genomic aberrations or 
insertions, cell purity (i.e. transplanted population containing iPSCs/ESCs with inherent teratoma 
potential) and cell of origin (i.e. the reduced risk of tumorigenicity with ASCs compared to iPSCs/ESCs, 
ESCs compared to iPSCs, and neonatal compared with adult cell-derived iPSCs). 
Figure S2: Schematic demonstrating the described potential mechanisms of immune recognition 
and rejection of stem cell grafts. (1) MHC-I incompatibility. CD8+ve cytotoxic T-cells recognize the 
MHC-I as non-self (e.g. allogeneic transplants) and with additional detection of co-stimulatory 
molecules, elicit an immunogenic response leading to rejection. (2) MHC-II incompatibility. MHC-II-
expressing antigen-presenting cells, present to CD4+ve T helper cells resulting in cytokine-induced 
inflammation and/or activation of B or T cell responses. (3) Minor histocompatibility complex (mHC) 
incompatibility. A selection of proteins expressed in the cell, including mitochondria derived proteins, 
may bind to and be presented by MHC-I.  These can be recognized as mHC antigens, and lead to 
immune-rejection. (4) ABO blood group antigen incompatibility. ABO blood group antigens can be 
detected by antibodies and activate the complement system. (5) Natural killer (NK) cell rejection. 
When bound to the MHC-I molecule, NK cell binding to NK cell lysis receptors and subsequent cell-
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killing is inhibited. In the absence of MHC-I, NK cells are free to bind to NK cell lysis receptors, and 
consequently elicit cell-killing.  Undifferentiated stem cells are generally considered not to express 
MHC-II, NK cell lysis receptors NKp30, NKp46, CD16 and NKp44 or co-stimulatory molecules CD40, 
B7.1 and B7.2.  Furthermore, stem cells are only considered to express low levels of MHC-I, although 
expression can be induced by IFN-γ. Expression of all of these molecules on the fully differentiated 
derivative however, is an important consideration when considering immunogenic tolerance.   
Figure S3: Stem cell imaging techniques. Representative diagram of the two main cell imaging 
strategies: direct labelling and indirect labelling. Direct methods require the labelling of the cell with 
a non-integrative product, such as quantum dots, which reside in the cytoplasm and can be detected 
via MRI, PET, SPECT or fluorescent imaging depending on the technique. Indirect labelling requires a 
genetic modification of the cell, through the insertion of a gene reporter, which is then detected by 
the appropriate imaging technique. Details of each technique are listed in table 3. 
 
 
 
 
 
ICTRP Trial ID Disease Cell type Trail stage Country Financial support 
Registration 
date 
NCT02122159 
Myopic Macular 
Degeneration 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I/II USA 
University of 
California, Los 
Angeles 
01/04/2014 
NCT02057900 
Ischemic Heart 
Disease 
Human 
Embryonic Stem 
Cell-derived 
CD15+ Isl-1+ 
Progenitors 
I France 
Assistance Publique 
- Hôpitaux de Paris 
17/09/2013 
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NCT01691261 
Acute Wet Age 
Related Macular 
Degeneration 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I USA/UK Pfizer 19/09/2012 
NCT01674829 
Advanced Dry 
Age-related 
Macular 
Degeneration 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I/II South Korea CHA Bio & Diostech 22/08/2012 
NCT01625559 
Stargardt's 
Macular 
Dystrophy 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I South Korea CHA Bio & Diostech 18/06/2012 
NCT01469832 
Stargardt's 
Macular 
Dystrophy 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I/II UK 
Advanced Cell 
Technology 
08/11/2011 
NCT01344993 
Advanced Dry 
Age Related 
Macular 
Degeneration 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I/II USA 
Advanced Cell 
Technology 
28/04/2011 
NCT01345006 
Stargardt's 
Macular 
Dystrophy 
hESC-derived 
Retinal 
Pigmented 
Epithelial cells 
I/II USA 
Advanced Cell 
Technology 
28/04/2011 
Table 1: List of embryonic stem cells clinical trials currently collated in the International Clinical Trial 
Registry Platform (ICTRP) by the World Health Organization. Only clinical trials phase I-III included.
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Assay Intended use Advantages Disadvantages 
Karyotyping 
(G-banding and/or Spectral)23, 25 
Assess genetic integrity 
Unbiased genome coverage. 
Can detect balanced translocations and 
inversions. 
Cell-level resolution 
Low genome resolution. 
Low throughput 
Comparative Genomic 
Hybridization arrays24, 26, 27, 29 
Assess genetic integrity 
High genome resolution. 
Can probe specific zones 
Does not detect changes in ploidy. 
Unable to detect balanced translocations and 
inversions. 
Population level resolution 
Comparative Large Scale 
Expression analysis28, 31, 146 
(e-Karyotyping) 
Assess genetic integrity 
Assess cell 
differentiation 
High genome resolution. 
Can probe specific zones. 
Expression profile and genetic integrity test 
at the same time. 
Indirect test for genetic integrity. 
Does not detect changes in ploidy. 
Unable to detect balanced translocations and 
inversions. 
Population level resolution 
Single Nucleotide Polymorphism 
analysis23, 26, 29 
Assess genetic integrity 
High genome resolution. 
Can probe specific zones. 
Does not detect changes in ploidy. 
Unable to detect balanced translocations and 
inversions. 
Population level resolution 
Standard histology and cell 
microscopy 97, 147 
Assess cell 
differentiation 
Cell-level resolution. 
Can detect incomplete and immature 
phenotypes or transformation 
Significant experience required. 
Invasiveness for in vivo and clinical use. 
Cannot discriminate between host and graft. 
Low throughput 
Standard molecular biology 
expression tools 
(northern and western blotting, 
ELISA, 2D protein gels, PCR 
related techniques)25, 32, 148 
Assess cell behavior and 
differentiation 
Can detect incomplete and immature 
phenotypes or transformation. 
Can discriminate between host and graft 
(depending on technique and application) 
Invasiveness for in vivo and clinical use. 
Population level resolution 
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in-situ hybridization and 
immunolabelling of endogenous 
transcripts/antigens 
(including bioluminescence and 
cell sorting techniques) 30, 149, 150 
Assess cell behavior and 
differentiation 
Cell preparation 
purification 
Cell level resolution. 
Combines histology and gene expression 
Can detect incomplete or immature 
phenotypes. 
Can discriminate between host and graft 
(with adequate probe or antibody) 
Invasiveness for in vivo and clinical use. 
Low throughput 
Mass spectrometry 
proteomics151, 152 
Assess cell behavior and 
differentiation 
High throughput. 
Unbiased proteome coverage. 
Can detect incomplete or immature 
phenotypes. 
Can discriminate between host and graft 
(with labelling) 
Significant experience required. 
Sensitivity can be an issue for low abundance 
proteins. 
Invasiveness for in vivo and clinical use. 
Standard toxicology studies153 
Assess toxicity and 
tumor formation 
potential in animals and 
humans 
Well established. 
Allows basic metabolic profiling of the host 
Requires combined use of other techniques (i.e. 
histology, profiling, etc.) 
3D imaging techniques 
(MRI, CT, PET scans)153 
Assess tumour 
formation in animals 
and humans. 
Assess status of 
graft/device 
Assess host status 
Non-invasive. 
Good spatial data. 
Radioactive labelling (PET) can detect 
specific targets. 
Only morphological data (MRI and CT). 
Use of X-rays (CT) and/or radioactive reagents 
(PET). 
Requires expensive infrastructure. 
Photoacoustic imaging 125, 154 
Assess tumor formation 
in animals and humans 
Non-invasive Low skin penetration 
Bioluminescence imaging 155 
Assess tumor formation 
in animals and humans 
Non-invasive Low skin penetration 
 
Table 2:  Available assays to assess the tumorigenic risk of stem cell therapeutics, describing the main uses of each technique along with advantages and 
disadvantage
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Strategy Imaging Modality Overview 
- Sensitivity 
- Spatial resolution 
- Duration of track 
Advantages Disadvantages 
Direct Cell 
Labelling 
MRI 100, 101, 115, 156, 157 
This technique is based on 
registration of change in 
electromagnetic properties 
of hydrogen atoms within a 
high-strength static 
magnetic field after a series 
of repetitive radiofrequency 
pulses and gradients. 
 
- 10-3-10-5 mol/L 
- 25-100 μm 
- Cell Lifetime (Diluted 
over time) 
- High spatial and 
temporal 
resolution 
- Combines 
functional and 
morphological 
visualization 
- No exposure to 
ionizing radiation 
- Clinically 
applicable 
- Additional 
anatomical and 
pathological 
information 
- Signal dilution over time 
- Low sensitivity 
- No discrimination between live 
and dead cells 
- May effect proliferation and 
cell morphology 
- Long term tracking is 
challenging 
- Difficult quantification 
- Requires large amount of 
contrast probe 
- Accumulation of contrast 
probes can be toxic 
- Needs expensive equipment 
Radionuclide 
imaging (PET and 
SPECT)100, 101, 115, 156 
Ex vivo cellular uptake of 
radionuclides as a contrast 
agent (depending on the 
isotope used the tracking 
period is different). 
- 10-10-10-12 mol/L 
- 1-2 mm 
- Dependent on isotope 
half life 
 
- Picomolar 
sensitivity 
- Good tissue 
penetration 
- Translation to 
clinical 
applications  
 
- Leakage of radionuclides 
- Limited time window  
- Low spatial resolution 
- Emission of ionizing radiation  
- Signal dilution over time 
Optical 
fluorescence 
imaging100, 158-160 
Cells are labelled ex vivo 
with quantum dots (QDs) or 
fluorophores. 
- 10-9 -10-12 mol/L 
- 2-3mm 
- 2-14 days (imaging), 8 
weeks (QDs: histology) 
- High sensitivity 
- High 
photostability 
(QDs)  
- Low resolution 
- Limited tissue penetration 
- No clinical application 
- QDs potentially cytotoxic 
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Table 3: List of strategies used to directly or indirectly label stem cells in vivo. The table offers an overview of all methods in use for the labelling and the 
tracking of stem cells, with pros and cons. It should be noted that for the photoacoustic tomography, the technique itself is so new that drawbacks have still 
to be underlined. The different techniques are further reviewed by James and Gambhir 161. QD quantum dots; G/RFP, green or red fluorescent protein. 
 
 
 
Indirect Cell 
Labelling  
 
Fluorescent 
Imaging161 
Cells are transduced with a 
gene which encodes for a 
fluorescent protein (GFP, 
RFP, etc) 
- 10-9 -10-12 mol/L 
- Up to 2 mm 
- Cell Lifetime 
- Longitudinal 
studies of stem 
cell viability 
- No alteration of 
cell phenotype or 
differentiation 
capacity 
- Controllable 
system  
- Genetic modification 
- Not suitable in humans 
 
Bioluminescence 
Imaging155, 162 
Cells are transduced with a 
bioluminescent reporter 
gene 
- 10-15-10-17 mol/L 
- 3-5 mm 
- Cell lifetime 
- Reduced false 
positives 
- High sensitivity 
- Low costs 
- Versatile 
- Genetic modification 
- Not suitable for clinical use, 
unless with a combinatorial 
approach 
Photoacoustic 
Tomography124, 125, 
163, 164 
Cells are transduced with a 
gene which replies to 
Photoacoustic waves with 
waves that are collected to 
produce a 3D image.  
 
Gold nanoparticles can also 
be used 
- 10-11-10-12 mol/L (gold 
nanoparticles) 
- Up to 7 cm 
- Cell lifetime 
 
- Low scattering in 
tissues 
- Multi-scale high 
resolution imaging 
of biological 
structures 
- 100% sensitivity 
- Background-free 
detection 
- Speckle-free 
- Genetic modification 
 
